| payload |
{"created_at":"2026-04-15T02:18:53.247 {"created_at":"2026-04-15T02:18:53.247056+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:336698575a43342a","evidence_event_ids":["evt_600d4bab1ba2"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001636178-26-000009.txt","as_of":"2026-04-15T02:18:53.247056+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001636178-26-000009.txt","company":"UNITED THERAPEUTICS Corp","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001636178-26-000009.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_0dd10a1ce5691368","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001636178-26-000009.txt","content_type":"text/plain","enriched_at":"2026-04-15T05:14:49.006778+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001636178-26-000009.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001636178-26-000009.txt","source_event_id":"evt_600d4bab1ba2","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"4","fp":"0dd186b6e0bfe350","kind":"sec_filing","published_at":"20260414","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-14","2026-04-13","2025-10-31","2023-03-15","2027-03-15"],"entities":[{"asset_class":"equity","name":"UNITED THERAPEUTICS Corp","relevance":"high","symbol":"UTHR","type":"issuer"},{"asset_class":"equity","name":"James Edgemond","relevance":"high","symbol":"","type":"reporting_person"},{"asset_class":"equity","name":"United Therapeutics Corporation Common Stock","relevance":"high","symbol":"UTHR","type":"security"}],"event_type":"listing","information_gaps":["What changed vs prior known state is not provided in the signal (no prior filing/position baseline included).","The cleaned text is truncated mid-sentence near the end; any additional transactions or totals beyond the shown lines may be missing.","Exact share counts sold/exercised totals are not fully summarized in the provided text; only line-item quantities and some weighted averages are visible without an explicit total."],"key_facts":["SEC filing: Form 4 for United Therapeutics Corp (issuer CI key 0001082554; ticker UTHR shown in text).","Filed as of date: 2026-04-14; conforming period of report: 2026-04-13.","Reporting owner: James Edgemond; role shown as CFO and Treasurer.","Security type shown: Common Stock.","The text states the transaction was executed pursuant to a Rule 10b5-1 trading plan entered into on October 31, 2025.","The text states the transaction involved stock option exercise and subsequent sale of shares.","The text provides multiple trade price ranges (e.g., $577.57 to $578.56; $578.59 to $579.56; $569.28 to $569.68; $570.40 to $571.38; $571.40 to $572.39; $572.40 to $573.36; $573.49 to $574.45), with weighted average prices reported for each line item."],"numeric_claims":[{"label":"Form filed as of date","value":"2026-04-14"},{"label":"Conforming period of report","value":"2026-04-13"},{"label":"Rule 10b5-1 plan entry date","value":"2025-10-31"},{"label":"Option exercise/sale weighted average price (example line)","value":"$135.42 (shown for Stock Option line)"}],"primary_claim":"Form 4 (United Therapeutics Corp) was filed on 2026-04-14 for transactions with a conforming period of report of 2026-04-13 by CFO/Treasurer James Edgemond, including stock option exercise and sale of common stock under a Rule 10b5-1 plan dated 2025-10-31.","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"United Therapeutics (UTHR) filed a Form 4 on 2026-04-14 covering transactions dated 2026-04-13 by reporting person James Edgemond (CFO and Treasurer). The filing indicates stock option exercise and subsequent sale of common shares under a Rule 10b5-1 trading plan entered on 2025-10-31.","topics":["SEC Form 4","insider trading","stock option exercise","share sale","Rule 10b5-1 trading plan"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 4 \u00b7 UNITED THERAPEUTICS Corp \u00b7 Filed 20260414","ticker":"UTHR","tickers":["UTHR"],"title":"UTHR filed 4","url":"https://www.sec.gov/Archives/edgar/data/1082554/0001636178-26-000009.txt"}}... |